Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Glob Antimicrob Resist ; 20: 282-284, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-32006754

RESUMO

OBJECTIVES: Mycoplasma hominis is one of the smallest free-living opportunistic human pathogens responsible for a diverse range of infections. However, knowledge regarding the genetic and pathogenic mechanisms of M. hominis is still very limited. This study aimed to investigate the genomic features of a multidrug-resistant M. hominis isolate recovered from a synovial fluid sample in China. METHODS: Antimicrobial susceptibility of M. hominis MH-1 was determined by broth microdilution. Genomic DNA was extracted and was sequenced using an Illumina HiSeq X Ten platform. De novo genome assembly was performed using SPAdes, and the draft genome was annotated using the NCBI Prokaryotic Genome Annotation Pipeline (PGAP). Core genome single nucleotide polymorphism (cgSNP) analysis between M. hominis MH-1 and all 25 M. hominis strains retrieved from the NCBI GenBank database was performed using BacWGSTdb server. RESULTS: Antimicrobial susceptibility testing showed that M. hominis MH-1 was resistant to macrolides and fluoroquinolones. The genome size was calculated as 720 262 bp, with 608 protein-coding sequences and a G + C content of 26.8%. Several antimicrobial resistance genes, virulence genes, genomic islands and insertion sequences were identified in the genome. Phylogenetic analysis showed that the strains retrieved from NCBI as well as M. hominis MH-1 were not epidemiologically related. The closest relative of M. hominis MH-1 was recovered from the USA, which differed by 5898 SNPs. CONCLUSION: This study reports the first genome sequence of a multidrug-resistant M. hominis isolate in China. These data may help to understand the genomic features and antimicrobial resistance mechanisms of this pathogen.


Assuntos
Farmacorresistência Bacteriana Múltipla , Mycoplasma hominis/classificação , Polimorfismo de Nucleotídeo Único , Líquido Sinovial/microbiologia , Sequenciamento Completo do Genoma/métodos , Composição de Bases , China , Fluoroquinolonas/farmacologia , Tamanho do Genoma , Genoma Bacteriano , Humanos , Macrolídeos/farmacologia , Testes de Sensibilidade Microbiana , Anotação de Sequência Molecular , Mycoplasma hominis/efeitos dos fármacos , Mycoplasma hominis/genética , Mycoplasma hominis/isolamento & purificação , Filogenia , Fatores de Virulência/genética
2.
PLoS One ; 8(11): e79698, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24244544

RESUMO

Soybean isoflavone (SIF) has anti-aging properties and many other biological functions; however, SIF is difficult to reach higher blood concentration due to its rapid metabolism. Therefore, it is of great value to design and produce a sustained-release formulation that is able to maintain a stable level of plasma concentrations. In this paper, soybean isoflavone sustained-release microsphere from chitosan and sodium alginate was prepared successfully. The important factors that determined the quality of the microspheres were the sodium alginate concentration in solution B, the ratio of soybean isoflavone to chitosan and the mixing speed. The relative yield, encapsulation efficiency and drug loading capability of SIF were much higher than the existing commercial formulations. In real gastrointestinal conditions, compared with the non-sustained release group, the release rate of SIF slowed down and the reaction time was prolonged. Animal experiments showed that sustained-release microspheres intensified the anti-aging potentials of SIF. Compared with the Non-sustained release (NSR) group mice, oral SIF/CHI microsphere treated mice were better in the Morris Water Maze Test (MWMT), the MDA level in the both plasma and brain of the sustained release (SR) group mice decreased, and SOD content was remarkably improved.


Assuntos
Quitosana/administração & dosagem , Quitosana/farmacocinética , Portadores de Fármacos , Glycine max/química , Isoflavonas , Microesferas , Alginatos , Animais , Antioxidantes/administração & dosagem , Antioxidantes/farmacocinética , Comportamento Animal/efeitos dos fármacos , Preparações de Ação Retardada , Feminino , Ácido Glucurônico , Ácidos Hexurônicos , Camundongos , Tamanho da Partícula , Coelhos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...